BR0113057A - Composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, e, método para produzir um efeito antiangiogênico e/ou efeito de redução da permeabilidade vascular em um animal de sangue quente em necessidade de tal tratamento - Google Patents
Composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, e, método para produzir um efeito antiangiogênico e/ou efeito de redução da permeabilidade vascular em um animal de sangue quente em necessidade de tal tratamentoInfo
- Publication number
- BR0113057A BR0113057A BR0113057-9A BR0113057A BR0113057A BR 0113057 A BR0113057 A BR 0113057A BR 0113057 A BR0113057 A BR 0113057A BR 0113057 A BR0113057 A BR 0113057A
- Authority
- BR
- Brazil
- Prior art keywords
- sub
- sup
- alkyl
- compound
- represents hydrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
"COMPOSTO, PROCESSO PARA A PREPARAçãO DE UM COMPOSTO, COMPOSIçãO FARMACêUTICA, USO DE UM COMPOSTO, E, MéTODO PARA PRODUZIR UM EFEITO ANTIANGIOGêNICO E/OU EFEITO DE REDUçãO DA PERMEABILIDADE VASCULAR EM UM ANIMAL DE SANGUE QUENTE EM NECESSIDADE DE TAL TRATAMENTO". A invenção refere-se a compostos de fórmula (I), em que qualquer um de G~ 1~, G~ 2~, G~ 3~, G~ 4~ e G~ 5~ é nitrogênio e os outros quatro são -CH- ou G~ 1~, G~ 2~, G~ 3~, G~ 4~ e G~ 5~ são todos -CH-; Z é -O-, -NH-, -S-, -CH~ 2~- ou uma ligação direta; Z é ligado a qualquer um de G~ 1~, G~ 2~, G~ 3~ e G~ 4~, que é um átomo de carbono livre; n é um inteiro de 0 a 5; qualquer um dos substituintes R^ 1^ pode ser ligado a qualquer átomo de carbono livre do grupo indol, azaindol ou indazol; m é um inteiro de 0 a 3; R^ a^ representa hidrogênio, R^ b^ representa hidrogênio ou outro valor como aqui definido; R^ 1^ representa hidrogênio, oxo, hidróxi, halogênio, C~ 1-4~alquila, C~ 1-4~alcóxi, C~ 14~alcóxiC~ 1-4~alquila, aminoC~ 1-4~alquila, C~ 1-3~alquilaminoC~ 1-4~alquila, di(C~ 13~alquilaminoC~ 1-4~alquila, di(C~ 1-3~alquil)aminoC~ 1-4~alquila, -C~ 1-5~alquil(anel B), em que o anel B é selecionado de azetidinila, pirrolidinila, piperidinila, piperazinila, N-metilpiperazinila, N-etilpiperazinila, morfolino e tiomorfolino; R^ 2^ representa hidrogênio, hidróxi, halogênio, ciano, nitro, trifluorometila, C~ 1-3~alquila, C~ 1-3~alcóxi, C~ 1-3~alquilsulfanila, -NR^ 3^R^ 4^ (em que R^ 3^ e R^ 4^, que podem ser iguais ou diferentes, cada um representa hidrogênio ou C~ 1-3~alquila), ou R^ 5^X^ 1^-(em que R^ 5^ e X^ 1^ são como definidos aqui) e seus sais, processos para a preparação de tais compostos, composições farmacêuticas contendo um composto de fórmula I ou um seu sal farmaceuticamente aceitável como ingrediente ativo e ao uso de um composto de fórmula I na manufatura de medicamento para a produção de um efeito antiangiogênico e/ou redutor da permeabilidade vascular em animais de sangue quente. Os compostos de fórmula I e seu sal farmaceuticamente aceitável inibem os efeitos de VEGF, uma propriedade de valor no tratamento numerosos estados doentios, incluindo câncer e artrite reumatóide.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00402255 | 2000-08-09 | ||
| PCT/GB2001/003533 WO2002012228A1 (en) | 2000-08-09 | 2001-08-07 | Cinnoline compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0113057A true BR0113057A (pt) | 2003-07-08 |
Family
ID=8173806
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0113057-9A BR0113057A (pt) | 2000-08-09 | 2001-08-07 | Composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, e, método para produzir um efeito antiangiogênico e/ou efeito de redução da permeabilidade vascular em um animal de sangue quente em necessidade de tal tratamento |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6887874B2 (pt) |
| EP (1) | EP1309587B1 (pt) |
| JP (1) | JP2004505966A (pt) |
| KR (1) | KR100834823B1 (pt) |
| CN (1) | CN1252065C (pt) |
| AT (1) | ATE419245T1 (pt) |
| AU (2) | AU7652101A (pt) |
| BR (1) | BR0113057A (pt) |
| CA (1) | CA2415022A1 (pt) |
| DE (1) | DE60137234D1 (pt) |
| ES (1) | ES2317923T3 (pt) |
| IL (2) | IL153805A0 (pt) |
| MX (1) | MXPA02012943A (pt) |
| NO (1) | NO326475B1 (pt) |
| NZ (1) | NZ523388A (pt) |
| WO (1) | WO2002012228A1 (pt) |
| ZA (1) | ZA200300221B (pt) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1553097T3 (da) | 1999-02-10 | 2010-12-13 | Astrazeneca Ab | Quinazolinderivat som angiogeneseinhibitor og mellemprodukter dertil |
| PT1676845E (pt) | 1999-11-05 | 2008-08-05 | Astrazeneca Ab | Novos derivados de quinazolina |
| JP2003525897A (ja) | 2000-03-06 | 2003-09-02 | アストラゼネカ アクチボラグ | 治 療 |
| CN1240688C (zh) * | 2000-04-07 | 2006-02-08 | 阿斯特拉曾尼卡有限公司 | 喹唑啉化合物 |
| WO2003064413A1 (en) | 2002-02-01 | 2003-08-07 | Astrazeneca Ab | Quinazoline compounds |
| TW200400034A (en) | 2002-05-20 | 2004-01-01 | Bristol Myers Squibb Co | Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors |
| WO2004041829A1 (en) * | 2002-11-04 | 2004-05-21 | Astrazeneca Ab | Quinazoline derivatives as src tyrosine kinase inhibitors |
| DK1625121T3 (da) | 2002-12-20 | 2010-05-10 | Pfizer Prod Inc | Pyrimidinderivater til behandling af abnorm cellevækst |
| US7109337B2 (en) | 2002-12-20 | 2006-09-19 | Pfizer Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| GB0318422D0 (en) * | 2003-08-06 | 2003-09-10 | Astrazeneca Ab | Chemical compounds |
| CA2566477A1 (en) | 2004-05-14 | 2005-11-24 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
| BRPI0510980A (pt) | 2004-05-14 | 2007-11-27 | Pfizer Prod Inc | derivados de pirimidina para o tratamento do crescimento anormal de células |
| CA2564199A1 (en) | 2004-05-14 | 2005-11-24 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
| WO2006028957A1 (en) * | 2004-09-03 | 2006-03-16 | Memory Pharmaceuticals Corporation | 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms |
| US7700595B2 (en) * | 2005-03-01 | 2010-04-20 | Wyeth Llc | Cinnoline compounds |
| MX2008010671A (es) * | 2006-02-21 | 2008-10-01 | Amgen Inc | Derivados de cinolina como inhibidores de fosfodiesterasa 10. |
| EP1991531A1 (en) * | 2006-02-28 | 2008-11-19 | Amgen Inc. | Cinnoline and quinoxaline derivates as phosphodiesterase 10 inhibitors |
| US20080190689A1 (en) * | 2007-02-12 | 2008-08-14 | Ballard Ebbin C | Inserts for engine exhaust systems |
| US8921533B2 (en) | 2011-07-25 | 2014-12-30 | Chromatin Technologies | Glycosylated valproic acid analogs and uses thereof |
| WO2014089177A2 (en) | 2012-12-04 | 2014-06-12 | Massachusetts Institute Of Technology | Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines |
| WO2014144715A1 (en) | 2013-03-15 | 2014-09-18 | Memorial Sloan-Kettering Cancer Center | Hsp90-targeted cardiac imaging and therapy |
| CN104370825B (zh) * | 2014-09-29 | 2017-04-19 | 人福医药集团股份公司 | 作为激酶抑制剂的取代杂环化合物及其制备方法和用途 |
| US10918627B2 (en) | 2016-05-11 | 2021-02-16 | Massachusetts Institute Of Technology | Convergent and enantioselective total synthesis of Communesin analogs |
| WO2018209239A1 (en) | 2017-05-11 | 2018-11-15 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
| US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
| CN113784962A (zh) | 2019-02-27 | 2021-12-10 | 加利福尼亚大学董事会 | 用于治疗脑部疾病的氮杂环庚三烯并-吲哚类和其他杂环 |
| WO2020247054A1 (en) | 2019-06-05 | 2020-12-10 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL81307A0 (en) | 1986-01-23 | 1987-08-31 | Union Carbide Agricult | Method for reducing moisture loss from plants and increasing crop yield utilizing nitrogen containing heterocyclic compounds and some novel polysubstituted pyridine derivatives |
| IL89029A (en) | 1988-01-29 | 1993-01-31 | Lilly Co Eli | Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them |
| CA2102780C (en) | 1991-05-10 | 2007-01-09 | Alfred P. Spada | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
| US5480883A (en) * | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| AU680870B2 (en) * | 1993-04-28 | 1997-08-14 | Astellas Pharma Inc. | New heterocyclic compounds |
| WO1998013350A1 (en) * | 1996-09-25 | 1998-04-02 | Zeneca Limited | Qinoline derivatives inhibiting the effect of growth factors such as vegf |
| NZ330571A (en) | 1996-10-01 | 1999-10-28 | Kyowa Hakko Kogyo Kk | Nitrogenous heterocyclic compounds that may contain sulphur or oxygen |
| AU734009B2 (en) | 1997-05-30 | 2001-05-31 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
| US6162804A (en) * | 1997-09-26 | 2000-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| GB9721437D0 (en) | 1997-10-10 | 1997-12-10 | Glaxo Group Ltd | Heteroaromatic compounds and their use in medicine |
| PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
-
2001
- 2001-08-07 WO PCT/GB2001/003533 patent/WO2002012228A1/en active IP Right Grant
- 2001-08-07 BR BR0113057-9A patent/BR0113057A/pt not_active IP Right Cessation
- 2001-08-07 IL IL15380501A patent/IL153805A0/xx unknown
- 2001-08-07 KR KR1020037001922A patent/KR100834823B1/ko not_active IP Right Cessation
- 2001-08-07 ES ES01954175T patent/ES2317923T3/es not_active Expired - Lifetime
- 2001-08-07 NZ NZ523388A patent/NZ523388A/en unknown
- 2001-08-07 JP JP2002518203A patent/JP2004505966A/ja active Pending
- 2001-08-07 US US10/333,592 patent/US6887874B2/en not_active Expired - Fee Related
- 2001-08-07 EP EP01954175A patent/EP1309587B1/en not_active Expired - Lifetime
- 2001-08-07 MX MXPA02012943A patent/MXPA02012943A/es active IP Right Grant
- 2001-08-07 AT AT01954175T patent/ATE419245T1/de not_active IP Right Cessation
- 2001-08-07 AU AU7652101A patent/AU7652101A/xx active Pending
- 2001-08-07 CA CA002415022A patent/CA2415022A1/en not_active Abandoned
- 2001-08-07 AU AU2001276521A patent/AU2001276521B2/en not_active Ceased
- 2001-08-07 DE DE60137234T patent/DE60137234D1/de not_active Expired - Fee Related
- 2001-08-07 CN CNB018139167A patent/CN1252065C/zh not_active Expired - Fee Related
-
2003
- 2003-01-05 IL IL153805A patent/IL153805A/en not_active IP Right Cessation
- 2003-01-08 ZA ZA200300221A patent/ZA200300221B/en unknown
- 2003-02-07 NO NO20030624A patent/NO326475B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| US20030212055A1 (en) | 2003-11-13 |
| CN1252065C (zh) | 2006-04-19 |
| KR20030022379A (ko) | 2003-03-15 |
| WO2002012228A1 (en) | 2002-02-14 |
| CA2415022A1 (en) | 2002-02-14 |
| JP2004505966A (ja) | 2004-02-26 |
| ES2317923T3 (es) | 2009-05-01 |
| IL153805A (en) | 2009-05-04 |
| KR100834823B1 (ko) | 2008-06-09 |
| NO20030624D0 (no) | 2003-02-07 |
| IL153805A0 (en) | 2003-07-31 |
| NO20030624L (no) | 2003-04-07 |
| ATE419245T1 (de) | 2009-01-15 |
| EP1309587B1 (en) | 2008-12-31 |
| MXPA02012943A (es) | 2003-05-15 |
| AU2001276521B2 (en) | 2006-05-25 |
| CN1446214A (zh) | 2003-10-01 |
| NZ523388A (en) | 2004-09-24 |
| DE60137234D1 (de) | 2009-02-12 |
| US6887874B2 (en) | 2005-05-03 |
| NO326475B1 (no) | 2008-12-08 |
| EP1309587A1 (en) | 2003-05-14 |
| AU7652101A (en) | 2002-02-18 |
| ZA200300221B (en) | 2004-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0113057A (pt) | Composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, e, método para produzir um efeito antiangiogênico e/ou efeito de redução da permeabilidade vascular em um animal de sangue quente em necessidade de tal tratamento | |
| NO991423D0 (no) | Qinolinderivater som inhiberer effekten av vekstfaktorer som VEGF | |
| BR0109828A (pt) | Composto, processo para a prepapação do mesmo ou de um sal deste, composição farmacêutica, uso do composto ou de um sal deste farmaceuticamente aceitável, e, método para a produção de um efeito antiangiogênico e/ou redutor da permeabilidade vascular em um animal de sangue quente em necessidade de tal tratamento | |
| CA2344290A1 (en) | Quinazoline derivatives | |
| BR9707495A (pt) | Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente | |
| ATE203524T1 (de) | Chinazolin-derivate | |
| MY129540A (en) | Quinazoline derivatives, pharmaceutical compositions containing them processes for their preparation and their use in the production of an antiangiogenic and/or vascular permeability reducing effect | |
| ATE390421T1 (de) | Aminoheterocyclen als vr-1 antagonisten zur behandlung von schmerzen | |
| BR0113078A (pt) | Uso de um composto, composto, processo para a preparação do mesmo, composição farmacêutica, e, método para produzir um efeito antiangiogênico e/ou redutor da permeabilidade vascular em um animal de sangue quente | |
| HUP0201722A2 (hu) | Gyógyászati készítmények alkoholizmus és alkoholfüggőség kezelésére | |
| ATE401080T1 (de) | (3-((chinazolin-4-yl)amino)-1h-pyrazol-1- yl)acetamid derivate und verwandte verbindungen als aurora kinase inhibitoren zur behandlung von proliferativen erkrankungen wie krebs | |
| EA200100725A3 (ru) | Новые бензотиадиазиновые соединения, способ их получения и их содержащие фармацевтические композиции | |
| HK1075656A1 (en) | New piperidinyl-alkylamino-pyridazinone derivatives, a process for the preparation thereof and pharmaceutical compositions containing said compounds | |
| ATE23150T1 (de) | Aminoethoxybenzylalkohol-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen. | |
| HUP0100751A2 (hu) | Új aril-vagy heteroaril-kinolinilfoszfonsav-származékok, eljárás előállításukra és ilyen vegyületeket tartalmazó gyógyszerkészítmények | |
| ATE25968T1 (de) | 1,1-diphenylpropanol-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen. | |
| RU2006131044A (ru) | Органические соединения | |
| ECSP003488A (es) | Derivados de 13- metileritromicina | |
| RU95122582A (ru) | Производные карбазола, обладающие 17, 20-лиазоингибирующей активностью, способ их получения, фармацевтический состав, способ производства лекарства, способ лечения млекопитающих и способ лечения рака предстательной железы | |
| RU94012551A (ru) | Бензамидные производные, способы их получения, фармацевтическая композиция и способ лечения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A E 10A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012. |